Table 2.
Patient characteristics of resected clinical stage I-II (AJCCv7) small cell lung cancer according to number of lymph nodes dissected (n = 1,584).
| Factors | Number of lymph nodes dissected | P value | ||
|---|---|---|---|---|
| ≥3 (n = 1,422) | <3 (n = 162) | |||
| Age | <70 | 847 (60%) | 100 (62%) | 0.5945 a |
| ≥70 | 575 (40%) | 62 (38%) | ||
| Sex | male | 643 (45%) | 70 (43%) | 0.6264 a |
| female | 779 (55%) | 92 (57%) | ||
| Race | whites | 1,301 (91%) | 148 (91%) | 0.9542 a |
| others | 121 (9%) | 14 (9%) | ||
| Insurance status | uninsured | X | X | 0.0194 b |
| insured | Y | Y | ||
| Institution | academic | 547 (38%) | 54 (33%) | 0.2020 a |
| others | 875 (62%) | 108 (67%) | ||
| Charlson-Deyo score | 0-1 | 1,200 (84%) | 136 (84%) | 0.8845 a |
| ≥2 | 222 (16%) | 26 (16%) | ||
| Year of diagnosis | 2004-2010 | 351 (25%) | 53 (33%) | 0.0263 a |
| 2011-2017 | 1,071 (75%) | 109 (67%) | ||
| Histology | SCLC NOS | 1,060 (75%) | 131 (81%) | 0.0776 a |
| others | 362 (25%) | 31 (19%) | ||
| Pathologic T stage | T0-1 | 863 (61%) | 100 (62%) | 0.7974 a |
| T2-4 | 559 (39%) | 62 (38%) | ||
| Pathologic N stage* | N0 | 1,122 (79%) | 124 (89%) | 0.0075 b |
| N1-2 | 295 (21%) | 16 (11%) | ||
| Tumor size | <30mm | 441 (31%) | 52 (32%) | 0.7773 a |
| ≥30mm | 981 (69%) | 110 (68%) | ||
| Resected margin status | other | 65 (5%) | 11 (7%) | 0.2105 a |
| negative | 1,357 (95%) | 151 (93%) | ||
| Adjuvant chemotherapy | yes | 908 (64%) | 97 (60%) | 0.3193 a |
| no/unknown | 514 (36%) | 65 (40%) | ||
| Adjuvant chest radiation | yes | 380 (27%) | 43 (27%) | 0.9609 b |
| no/unknown | 1,042 (73%) | 119 (73%) | ||
AJCC, American Joint Commission on Cancer; SCLC, small cell lung cancer; NOS, not otherwise specified, X and Y number less than 10 cannot be reported according to NCDB agreement.
a
χ2 test.
b
Fisher’s 2-sided exact test.
*cases with pathologic NX (n = 37) were excluded.